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Introduction: New tyrosine kinase inhibitor treatments for chronic myeloid leukemia based on nilotinib, 
dasatinib and imatinib have improved patient quality of life and have turned chronic myeloid leukemia 
from a fatal disease into a chronic disease.
Objective: To evaluate the cost-effectiveness of nilotinib, 600 mg, and dasatinib, 100 mg, each 
compared to imatinib, 400 mg, as first-line therapy in chronic myeloid leukemia in Colombia from a 
third-party payer’s perspective.
Materials and methods: A cost-effectiveness analysis was performed using a Markov model to 
evaluate a hypothetical cohort of one hundred 55 year-old patients with newly diagnosed chronic 
myeloid leukemia in the chronic phase, and the time horizon for the baseline case was established 
as being until the end of life. Progression-free life-years saved were considered the primary outcome. 
Transition probabilities for major molecular response, disease progression to accelerated phase or 
blast crisis, and chronic myeloid leukemia related deaths were analyzed in the model for each arm. A 
3% discount rate was applied to all costs and patient outcomes. Model robustness was evaluated using 
both univariate and multivariate Montecarlo sensitivity analysis. 
Results: Nilotinib was higher in expected progression-free life-years saved (15.21 vs. 12.64 for 
imatinib), followed by dasatinib (14.91 vs. 14.54 for imatinib). Imatinib had lower total lifetime costs. 
The incremental cost-effectiveness ratio was US$ 33,120.36 in the nilotinib arm and US$ 514,939.08 
in the dasatinib arm per progression-free life-years (PF-LYs) saved, each compared to imatinib. When 
analyzing nilotinib versus dasatinib indirectly, nilotinib was found to be dominant due to higher efficacy 
(2.25 PF-LYs) and lower costs (US$ 44,674) in the baseline case. The average estimated cost to 
manage disease progression per year was US$ 101,978.78, considered to be the threshold. 
Conclusion: In Colombia, using PF-LYs as the efficacy outcome, nilotinib is highly cost-effective when 
compared to imatinib and dominant vs. dasatinib in first-line therapy for CML in chronic phase.
Key words: Protein-tyrosine kinases; leukemia, myelogenous, chronic, BCR-ABL positive; costs and 
cost analysis; drug evaluation.
doi: http://dx.doi.org/10.7705/biomedica.v34i1.1446
Análisis de costo-efectividad de nilotinib, dasatinib e imatinib como terapia de primera línea en 
leucemia mieloide crónica en Colombia, 2012
Introducción. Los nuevos inhibidores de la tirosina cinasa para tratar la leucemia mieloide crónica 
basados en nilotinib, dasatinib e imatinib, mejoraron la calidad de vida de los pacientes y la tornaron 
en enfermedad crónica.
Objetivo. Evaluar el costo-efectividad de nilotinib, 600 mg, y dasatinib, 100 mg, comparados con 
imatinib, 400 mg, como terapia de primera línea en leucemia mieloide crónica desde la perspectiva del 
tercero pagador en Colombia.
Materiales y métodos. Se analizó el costo-efectividad mediante un modelo de Markov con ciclos 
trimestrales, que evaluó una cohorte hipotética de 100 pacientes de 55 años recién diagnosticados con 
leucemia mieloide crónica en fase crónica en un horizonte temporal hasta el final de la vida. El desenlace 
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primario fueron los años de vida ganados libres de progresión. Se analizaron las probabilidades de 
transición para respuesta molecular mayor, progresión de la enfermedad y muerte relacionada con la 
leucemia mieloide crónica en el modelo para cada grupo. Se aplicó una tasa de descuento de 3 % a 
los costos y resultados de los pacientes. La solidez del modelo se evaluó por medio de un análisis de 
sensibilidad de tipo Montecarlo.
Resultados. Nilotinib fue mayor en años de vida ganados libres de progresión esperados (15,21 
Vs. 12,64 para imatinib), seguido por dasatinib (14,91 Vs. 14,54 para imatinib). El grupo tratado con 
imatinib fue la opción menos costosa y menos efectiva. La relación costo-efectividad ‘incremental’ 
(sic.) fue de US$ 33.120 en el grupo de nilotinib y de US$ 514.939,08 en el grupo de dasatinib por 
año de vida ganado libre de progresión comparados con imatinib. Al comparar indirectamente nilotinib 
con dasatinib, nilotinib fue dominante debido a su mayor eficacia (2,25 años de vida ganados libres de 
progresión) y menor costo (US$ 44.674). El costo promedio estimado para manejar la progresión de la 
enfermedad por año fue US$ 101.978,78 considerado como umbral. 
Conclusión. Usando como medida de efectividad los años de vida ganados libres de progresión, en 
Colombia el nilotinib es altamente costo-efectivo frente al imatinib y dominante cuando se compara 
con dasatinib para el tratamiento de primera línea de pacientes con leucemia mieloide crónica en 
fase crónica. 
Palabras clave: proteínas tirosina quinasas, leucemia mielogenosa crónica BCR-ABL positiva, costos 
y análisis de costo, evaluación de medicamentos.
doi: http://dx.doi.org/10.7705/biomedica.v34i1.1446
Chronic myeloid leukemia (CML) was the first 
malignant disease in which an acquired genetic 
anomaly was demonstrated as the final trigger in a 
chronic myeloproliferative syndrome characterized 
by a translocation between chromosomes 9 and 
22, giving rise to the formation of the so-called 
Philadelphia chromosome (Ph) and the creation of 
a new fused gene, BCR-ABL. This gene codifies 
a chimeric BCR-ABL protein that presents an 
elevated tyrosine kinase (TK) activity, which 
increases the survival and proliferation of cells and 
inhibits apoptosis (1).
CML represents approximately 10 to 15% of all 
leukemias, and the average risk that a person 
has of developing CML during his or her lifetime is 
estimated at 1 in 625. This disease is slightly more 
common in men than in women and more common 
in white subjects than in black subjects (2,3) with 
an average diagnosis age of 55 years (4). In the 
United States, the incidence is 1 to 1.5 cases per 
100,000 inhabitants (5,6).
Disease clinical progression can be divided into 
three primary phases: The chronic phase (1st), 
during which 90% of patients are diagnosed, may 
last between three and eight years. Blood cells 
retain their capacity to differentiate themselves 
normally, until the illness progresses to the 
accelerated phase (2nd), during which immature 
cells begin to be detected during blood circulation, 
and lastly, the blast crisis phase (3rd), characterized 
by +30% of immature cells (blasts) in circulation, 
including extramedullary infiltrates associated with 
an increase in splenomegaly. During blast crisis, 
or the terminal phase of the disease, the disease 
transforms into acute myeloid leukemia (AML) in 
85% of cases and into acute lymphoblast leukemia 
(ALL) in 10-15% of cases (7). During this phase, a 
patient’s survival period decreases to months and 
even weeks (8).
The main purpose of treatment for CML includes 
eradicating the leukemic clone from the bone 
marrow or maintaining the chronic phase with 
sustained remission and minimal toxicity from 
the treatment (7). Current treatment focuses on 
counteracting and slowing the disease progression, 
stopping tyrosine kinase activity, blocking the ATP-
joining region, blocking dimerization, and generating 
antibodies against the tyrosine receptor (9).
The introduction into clinical practice of tyrosine 
kinase inhibitors (TKI) that specifically block 
the enzymatic action of the fusion protein BCR-
ABL became a significant contribution to the 
management of CML (10). The use of new 
treatments based on imatinib, nilotinib and 
dasatinib have improved the patients’ quality of 
life and changed the natural history of the disease, 
transforming it from a disease that tended to be 
fatal to a chronic disease (8).
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The history of CML treatment has allowed for 
partial understanding of the biology of cancer 
and the development of highly specific inhibitors 
directed against some of the genetic abnormalities 
of the disease. Until a few years ago, there were 
limitations in the treatment of this condition; 
nevertheless, the progress of basic and clinical 
research has allowed for changes in response 
rates, quality of life and the survival of affected 
subjects. However, imatinib mesylate and second-
generation tyrosine kinase inhibitors (nilotinib, 
dasatinib and bosutinib) have not managed to stop 
disease progression, but they have been able to 
modify the progression of the blast crisis (11).
The annual mortality rate for CML is less than 10% 
for the first two years after diagnosis (10,11). 
Survival after five years in low, intermediate and 
high-risk groups is 76%, 55% and 25%, respectively, 
and for subjects in the accelerated and blast phases 
it is lower than 10% and 5%, respectively (10,11).
Nilotinib and dasatinib were initially developed for 
the treatment of patients resistant or intolerant to 
imatinib. In recent studies these have separately 
demonstrated superiority to imatinib in terms 
of progression free survival (PFS) and major 
molecular response (MMR) as 1st-line treatment 
in newly diagnosed patients (12-16). These efficacy 
outcomes created the need for a health economics 
evaluation in Colombia to help in decision making. 
The aim of this study was to evaluate the cost-
effectiveness of nilotinib, 600 mg, and dasatinib, 
100 mg, each compared to imatinib, 400 mg, as 
first line therapy in CML in Colombia from a third-
party payer’s perspective.
Materials and methods
Markov model
A cost-effectiveness analysis was performed from 
a third-payer perspective using a Markov chain 
model (figure 1) with quarterly cycles, based upon 
a decision-making tree that simulates the natural 
history of the disease from a temporary standpoint 
until the end of life.
As a case study, a patient with an average age of 55 
years (average age of disease onset) (4), recently 
diagnosed with CML in the chronic phase, who had 
not received any other treatment in each branch of 
treatment was considered.
The model assumes that all patients admitted are 
newly diagnosed and found to be in the chronic 
stage of disease and may or may not reach major 
molecular response (MMR). Those not in MMR may 
progress (to accelerated phase or blast crisis phase). 
Patients in the accelerated phase may remain so or 
go on to the blast phase and, once in the accelerated 
or blast phase, may die as a result of the disease. 
During any of the stages, patients may experience 
adverse events. Lastly, patients may die at any 
moment for any other reason (figure 2). The model 
does not include a state of voluntary withdrawal or 
suspension of treatment, since this would represent 
implications that would adversely affect the model.
Patients newly
diagnosed with
CML (CP)
MMR
Adverse event
Progression
(AP/BC)
Adverse event
Death
Non-CML related
Death
CML-related
Death
Death
MMR
No MMR
Figure 1. Decision-making tree model
CML: Chronic myeloid leukemia; CP: Chronic phase; MMR: Major molecular response; AP/BC: Accelerated phase, blast crisis
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Clinical data
As a starting point, the literature available in the 
Pubmed, LILACS, and Cochrane Library databases, 
as well as in the Trip Database and gray literature, 
were reviewed using the following keywords: 
nilotinib, dasatinib, imatinib, chronic myeloid 
leukemia, BCR-ABL, tyrosine kinase, as well as the 
expressions Cost-effectiveness analysis, costs and 
economic assessment, in order to find information 
on effectiveness and safety in the treatment of the 
disease and the selected comparisons. Phase III 
studies, systematic reviews, economic assessments 
and medical practice guides were selected. We did not 
include expert opinions, or narrative non-systematic 
reviews or phase-I/II clinical trials. We excluded 
studies evaluating the molecular composition of the 
medications, as well as case reports or case series.
Search strategies identified 442 studies, starting 
in 2000 and with a cut-off date of November 2011; 
when applying the inclusion criteria, 191 studies 
were selected on Pubmed, and from these, the 102 
most pertinent publications in terms of their subject 
and study objective were selected. These were: 
Six clinical practice guides; 17 cost-effectiveness 
analyses and other economic assessments; 19 
systematic reviews; 60 clinical trials. 
Studies were included if they involved: 
• Randomized controlled trials or systematic reviews 
of randomized controlled trials.
• Adults with chronic phase chronic myeloid leukemia 
resistant to any treatment specifically directed 
against chronic myeloid leukemia.
• Dasatinib, nilotinib or imatinib treatments (standard 
dose).
• Imatinib or nilotinib comparators where the 
treatment is dasatinib; imatinib or dasatinib where 
the treatment is nilotinib, dasatinib, or nilotinib.
For the cost-effectiveness review, the inclusion and 
exclusion criteria were the same as for the clinical 
effectiveness review, except in the case of study 
design, where full cost-effectiveness analyses, 
cost-utility analyses, and cost-benefit analyses 
were included.
Publications about two fundamental studies were 
also selected, which served as the source for this 
assessment: ENESTnd (12,13) and DASISION 
(14,15). Likewise, publications were identified 
that served as a basis for knowledge about the 
natural history of the disease and the technologies 
assessed. Publications were found that had the 
objective of assessing recent phase III clinical trials 
that compared nilotinib or dasatinib with imatinib in 
recently diagnosed CML (16-18).
No simultaneous studies were found and the duration 
of the clinical trials selected (24 months) was short 
(compared to the natural history of disease) but 
showed convincing results. There are other studies 
Newly diagnosed
CML (CP)
Sub-optimal
response / failure
(No MMR)
Progression
Accelerated
phase (AP)
Blast crisis
(BC)
Optimal response
(MMR)
Adverse
event
Death 
CML/Non -CML
related
Figure 2. Markov model design
CML: Chronic myeloid leukemia; CP: Chronic phase; MMR: Major molecular response
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that correspond to second-line management that 
are not applicable for this analysis.
The ENESTnd study evaluated nilotinib versus 
imatinib and, at the same time, the DASISION 
study evaluated dasatinib versus imatinib; both 
studies published their results at 12 (12-14), 18 
(presented as abstracts in ASH 2010) and 24 (13, 
15) months. Although the populations studied 
in these two studies were similar, the manner 
of measuring efficacy was different in that, for 
the ENESTnd study, major molecular response 
(MMR) was the primary point for results, whereas 
in the DASISION study, this result was the final 
secondary point (best response reached). Both 
trials reported MMR by risk group category at 12, 
18 and 24 months.
The American Cancer Society clinical practice 
guide (3), the ESMO Guidelines Working Group 
(19), and the Consensus Guide for the Diagnosis 
and Treatment of CML in Colombia (20) recommend 
imatinib at a dose of 400 mg/QD as a first treatment 
option. On the other hand, the results of the 
ENESTnd and DASISION studies showed efficacy 
benefits for first-line nilotinib and dasatinib in 
doses of 300 mg/BID and 100 mg/QD, respectively. 
In fact, this treatment regimen has been 
recommended by the National Comprehensive 
Cancer Network (2, 19,21) as an alternative choice 
for patients in the chronic phase.
Due to a lack of head-to-head trials of safety and 
efficacy on first-line treatment between nilotinib and 
dasatinib for CML, a four-branch parallel analysis 
was performed (comparing nilotinib vs. imatinib 
and dasatinib vs. imatinib), using the information 
from these two available clinical studies. A final 
comparison between nilotinib and dasatinib was 
made indirectly using the Boucher method (22), 
considering the similarity of the results of each 
analysis for the group receiving imatinib.
Progression-free time measured in progression-free 
life-years (PF-LYs) was selected as the outcome of the 
analysis, considering that the analysis emphasizes 
first-line treatment and the primary success is 
getting the patient to remain in the chronic phase. 
Health-related quality of life was not considered 
as an outcome because in Colombia there is no 
available information to date in that regard, and its 
extrapolation between countries is arguable. 
Transition probabilities for major molecular 
response (MMR), disease progression to the 
accelerated phase or blast crisis (AF/BC), and 
CML-related death were included in the model 
for each branch, considering the duration of each 
cycle (quarterly) and the stage within the model 
to which it was applied according to the literature 
review, and estimated according to information 
from clinical trials ENESTnd (12,13) (12, 18 and 
24 months), and DASISION (14-15) (12, 18 and 24 
months), which was validated by clinical experts. 
In all branches, the probabilities of presenting with 
grade 3/4 hematological adverse events were 
included for each type of treatment obtained from 
those studies (12-15) as shown in table 1.
Knowing that effectiveness is given for 24 months, 
a comparative analysis was performed with the 
IRIS study, which has reported the results of a 
7-year follow-up (23). Keeping in mind that the 
trend in the three studies was similar, it was 
assumed that performance over time from an 
efficacy point of view would be maintained with 
equal tendency as it figures into the probabilities 
for subsequent cycles.
Assessment of costs
The costs of the medications were calculated by 
taking the average sales price to the distributor of 
nilotinib, of imatinib and dasatinib, and the prices 
regulated by the State as the maximum chargeable 
price according to Resolution 2569 of 2012 (24) 
(table 2).
Each stage included the cost of healthcare as 
established according to the 2011 insurance 
price databases and validated with grounds on 
the recommendations of the European Leukemia 
Net (25,26) for the treatment of chronic myeloid 
leukemia and the accepted clinical recommendation 
guidelines (2,20,22) (table 2).
In order to establish the cost of the stage of 
progression (adsorbent stage), the total average 
cost was estimated to include: hospital costs, 
medications, diagnostic imaging, consumables, 
procedures, laboratory tests and medical care, 
differentiating them from their beginning (first 
trimester) and subsequent periods (table 3). Bone 
marrow transplant costs were not included in the 
progression costs due to the age of the patients in 
the baseline case.
According to DANE (27) vital statistics registries 
(2000-2008), sepsis occurred as a direct cause of 
death in 16.54% and hemorrhagic shock, in 19.60%, 
and according to the data collected from the service 
usage databases, the average cost estimates for 
care prior to death would be US$ 8,713.
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Table 1. Transition probabilities
Name Nilotinib, 300 mg/BID
n=282†
Imatinib, 400 mg/QD
n=283†
Source
Major molecular response at 3 months
Major molecular response at 6 months
Major molecular response at 9 months
Major molecular response at 12 months
Major molecular response at 18 months
Major molecular response at 24 months
Progression to accelerated phase                   
or blast phase at 12 months
Progression to accelerated phase                   
or blast phase at 18 months
Progression to accelerated phase                 
or blast phase at 24 months
Neutropenia at 12 months
Thrombocytopenia at 12 months
Anemia at 12 months
Neutropenia at 18 months
Thrombocytopenia at 18 months
Anemia at 18 months
Neutropenia at 24 months
Thrombocytopenia at 24 months
Anemia at 24 months
0.0909677419
0.2679043255
0.1532983610
0.0956699074
0.0956699074
0.0956699074
0.002313398
0
0
0.03
0.025
0.00805
0
0
0
0.03
0.025
0.0039
0.0101433692
0.1138541438
0.0700813075
0.0502418890
0.0566616005
0.0566616005
0.010703911
0.010703911
0.010703911
0.050179211
0.021577061
0.012544803
0
0
0
0.005017921
0.021577061
0.012544803
Saglio. ENESTnd, 2010 (12)
Saglio. ENESTnd, 2010 (12)
Saglio. ENESTnd, 2010 (12)
Kantarjian HM, 24-month minimum follow-up 
of the phase 3 randomised ENESTnd trial (13)
Presented by Hughes TP. In ASH 2010
Kantarjian HM, 24-month minimum follow-up 
of the phase 3 randomised ENESTnd trial (13)
Saglio. ENESTnd.2010 (12)
Presented by Hughes TP. In ASH 2010
Kantarjian HM, 24-month minimum follow-up 
of the phase 3 randomised ENESTnd trial (13)
Saglio. ENESTnd, 2010 (12)
Saglio. ENESTnd, 2010 (12)
Saglio. ENESTnd, 2010 (12)
Presented by Hughes TP. in ASH 2010
Presented by Hughes TP. in ASH 2010
Presented by Hughes TP. in ASH 2010
Kantarjian HM, 24-month minimum follow-up 
of the phase 3 randomized ENESTnd trial (13)
Kantarjian HM, 24-month minimum follow-up 
of the phase 3 randomized ENESTnd trial (13)
Kantarjian HM, 24-month minimum follow-up 
of the phase 3 randomized ENESTnd trial (13)
Name Dasatinib, 100 mg/QD 
n=258†
Imatinib, 400 mg/QD
n=258†
Source
Major molecular response at 3 months
Major molecular response at 6 months
Major molecular response at 9 months
Major molecular response at 12 months
Major molecular response at 18 months
Major molecular response at 24 months
Progression to accelerated phase         
or blast phase at 12 months
Progression to accelerated phase                
or blast phase at 18 months
Progression to accelerated phase                 
or blast phase at 24 months
Neutropenia at 12 months
Thrombocytopenia at 12 months
Anemia at 12 months
Neutropenia at 18 months
Thrombocytopenia at 18 months
Anemia at 18 months
Neutropenia at 24 months
Thrombocytopenia at 24 months
Anemia at 24 months
0.0800000000
0.2084095064
0.1662817552
0.1184049475
0.1149658628
0.1149658628
0.005877196
0.0013
0
0.0525
0.0475
0.025
0
0
0
0.005
0.0475
0.0050
0.0040000000
0.0783177580
0.1082583903
0.1292887449
0.0998191724
0.0998191724
0.009047554
0.001507926
0
0.05
0.025
0.0175
0
0
0
0.05
0.025
0.0175
Kantarjian H, DASISION 2010 (14)
Kantarjian H, DASISION 2010 (14)
Kantarjian H, DASISION 2010 (14)
Kantarjian H, DASISION 2010 (14)
Presented by Shah N. in ASH 2010.
Kantarjian HM, 2-year follow-up from a         
randomized phase 3 trial (DASISION) (16)
Kantarjian H, DASISION 2010 (14)
Presented by Shah N. in ASH 2010.
Kantarjian HM, 2-year follow-up from a         
randomized phase 3 trial (DASISION) (16)
Kantarjian H, DASISION 2010 (14)
Kantarjian H, DASISION 2010 (14)
Kantarjian H, DASISION 2010 (14)
Presented by Shah N. in ASH 2010.
Presented by Shah N. in ASH 2010.
Presented by Shah N. in ASH 2010.
Kantarjian HM, 2-year follow-up from a                 
randomized phase 3 trial (DASISION) (16)
Kantarjian HM, 2-year follow-up from a                
randomized phase 3 trial (DASISION) (16)
Kantarjian HM, 2-year follow-up from a                 
randomized phase 3 trial (DASISION) (16)
Source: Created by the authors with data from the aforementioned sources (12,13,14-16)
* Major molecular response (MMR) is defined as a decrease in more than three logarithms of the BCR/ABL transcript (≤ 0.1%). 
† ITT Population
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Discount rate
Most pharmacoeconomic analyses agree that 
costs should be discounted in any study with a time 
horizon longer than one year (28). The discount is 
used to convert future costs into present values, 
allowing for the creation of useful economic data, 
taking into account costs and benefits for several 
years. Although the appropriate discount rate is 
controversial and may vary over time, according 
to the economic environment, the costs and health 
benefits were chosen objectively.
The results were presented as total values reached 
from a temporary standoint, and the incremental cost-
effectiveness ratios (ICER) were analyzed by applying 
an annual discount rate of 3% to both costs and 
outcomes, keeping in mind the recommendations 
of different international guidelines.
Premises
Due to the absence of an official cost-effectiveness 
threshold in Colombia for the analyzed outcome, 
all comparisons were made by taking average 
estimated costs for the treatment of patient disease 
progression for one trimester (cycle) as a reference, 
understanding that this is the therapeutic goal and 
the profits earned over time could be comparable 
to the annual cost of US$ 101,978.78.
In order to determine the robustness of the 
model and control over uncertainty, a univariable 
and multivariable Montecarlo sensitivity analysis 
was performed with variations of ±20% in all of 
the variables, assuming that all of them behaved 
normally.
Ethical aspects 
The ethical principles regarding human research 
contained in the standards for health research in 
Colombian Ministry of Health Resolution 8430 of 
1993 were considered. According to article 11 of 
that Resolution, this study is a research without 
risk, as the information used is retrospective, 
without any intervention or modification involving 
biological, physiological, psychological, social 
variables or individuals participating in the study. 
However, records of the data generated from the 
different variables were used for the analysis of 
cost-effectiveness (29).
Results
Table 4 shows the data obtained in the deterministic 
analysis within the baseline case for each of the 
four branches with and without discount. The 
most effective option within the model was the 
one using nilotinib followed by dasatinib (15.21 
and 14.91 PF-LYs, respectively) as opposed to 
imatinib (12.64 and 14.54 PF-LYs, respectively). 
The branch treated with imatinib was the least 
expensive option of the three.
Table 2. Estimated health costs per model cycle
Price of medications according to their presentation per model cycle
Medication Cycle cost (US$)    Source
Imatinib, 
400 mg/QD
Dasatinib, 
100 mg/QD
Nilotinib, 
300 mg/BID
7,593.00
10,993.22
8,982.21
Resolution 2569
of 2012 (25)
Resolution 2569
of 2012 (25)
Resolution 2569
of 2012 (25)
Healthcare costs and adverse events estimated per model cycle
Description Cycle cost (US$)    Source
Cost after 3 months 
Cost after 6 months 
Cost after 12 months 
Neutropenia 
Thrombocytopenia
Anemia
866.77 
951.67 
1,356.43 
2,065.85 
1,553.04 
1,478.85 
Payer Database
Payer Database
Payer Database
Payer Database
Payer Database
Payer Database
Table 3. Progression costs per cycle
First trimester progression
Description Cycle cost (US$) Source
Hospital
Imaging
Consumables
Medications
Procedures
Paraclinical testing
Total
5,018.33
717.63
1,528.88
13,820.72
1,764.74
2,644.40
25,494.69
Payer Database
Payer Database
Payer Database
Payer Database
Payer Database
Payer Database
Second trimester and beyond
Description Cycle cost (US$) Source
Hospital
Imaging
Consumables
Medications
Procedures
Paraclinical testing
Total
5,018.33 
717.63 
1,528.88 
13,820.72
1,764.74 
3,283.61 
26,133.90
Payer Database
Payer Database
Payer Database
Payer Database
Payer Database
Payer Database
Table 4. Costs and outcomes with and without discount for 
baseline case
Branch
Non-discounted Discounted
PF-LY
Costs 
(US$)
PF-LY
Costs 
(US$)
Nilotinib
Imatinib (Nilo)*
Dasatinib
Imatinib (Dasa)*
20.90
17.06
20.46
19.93
945,864
836,544
1,007,284
750,018
15.21
12.64
14.91
14.54
688,562
603,477
733,236
545,265
*Comparisons from ENESTnd and DASISION studies (12-16)
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From total costs, 7.56% was attributed to the 
treatment of this type of patient, 21.76% to the 
costs of the technologies analyzed, and adverse 
events represented 12.13% of the total cost in the 
different branches, while the remaining 58.55% 
were progression costs. 
The increments for the data with and without 
discount and the respective incremental cost-
effectiveness ratio (ICER) are presented in table 
5, where it is observed that the most cost-effective 
option is the use of nilotinib, which has an incremental 
effectiveness of 2.57 PF-LYs and a cost of $ 5,085, 
in comparison with imatinib. The ICER showed that 
the cost per PF-LYs was $ 33,120 when comparing 
nilotinib with imatinib, as opposed to $ 514,939 
when comparing dasatinib with imatinib. When 
performing an indirect comparison between nilotinib 
and dasatinib, an extended dominance was shown 
equaling greater effectiveness (2.25 PF-LYs) and a 
lower incremental cost ($ 44,674) in the conditions 
of the baseline case.
Sensitivity analysis
A univariable analysis was performed from a 
temporary standpoint at 10 and 20 years (table 
6), and with changes in the discount rate (5% and 
0%), showing that the results favoring nilotinib had 
been maintained.
The multivariable Montecarlo analysis with 1,000 
repetitions is shown with point graphs (Scatter Plot) 
that demonstrate that nilotinib maintains its cost-
effectiveness versus imatinib in more than 99% 
of the cases with variations of ±20% (figure 3). 
Likewise, it is shown that dasatinib demonstrates 
2.2% cost-effectiveness versus imatinib, keeping 
the proposed threshold in mind. 
Figure 4 shows the comparison between dasatinib 
and nilotinib,revealing that nilotinib was better in all 
cases, as it is 10.91% cost-effective and dominant 
by 70.67% within the outcome analyzed.
Discussion
The results show similarities to the clinical trial 
reports: the clinical effectiveness of nilotinib versus 
comparable drugs by virtue of a greater proportion 
of patients who reach major molecular response 
and accordingly a lower progression rate (30) than 
that reported recently in several publications (31-
33, Savova A, Petrova G. PCN27 Budget impact 
analysis for chronic myeloid leukemia therapy in 
Bulgaria. Value Health. 2011;14:A438. http://dx.doi.
org/10.1016/j.jval.2011.08.1128).
A head-to-head trial of the efficacy and safety of 
these two agents is necessary in order to estimate 
the different therapeutic effects of these first 
generation technologies.
Table 5. Incremental relationship for costs and outcomes with and without discount for the baseline case
Branch Non-discounted incremental Discounted incremental ICER
PF-LY Costs (US$) PF-LY Costs (US$) Cost/Progression-free
life-year gained (US$)
Nilotinib vs. imatinib 
Dasatinib vs. imatinib 
Nilotinib vs. dasatinib 
3.84
0.53
3.38
109,319.61 
257,265.50 
 (61,420.22)
2.57
0.37
2.25
  85,084.91 
187,971.04 
 (44,674.02)
  33,120.36
514,939.08 
Dominant
Table 6. Univariable sensitivity analysis modifying the temporal viewpoint
Comparison Discounted PF-LY 
incremental
Discounted costs (US$) incremental ICER
Cost (US$)/Progression-free life-year gained
10 years
Nilotinib vs. imatinib
Dasatinib vs. imatinib
Nilotinib vs. dasatinib
0.92
0.15
0.78
57,958.37
103,904.31
24,249.21
62,736.60
686,337.95
Dominant
20 years
Nilotinib vs. imatinib
Dasatinib vs. imatinib
Nilotinib vs. dasatinib
2.13
0.31
1.86
79,682.76
168,020.12
39,760.16
37,453.68
549,027.17
Dominant
Source: Data calculated by the authors
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There are no similar comparisons to those 
presented here, but the individual results of 
nilotinib and dasatinib versus imatinib were similar 
to other recently-developed studies (34,35), which 
concluded that nilotinib is cost-effective in patients 
with newly diagnosed chronic phase Philadelphia 
chromosome-positive CML initiating therapy with 
TKI (tyrosine kinase inhibitor) after such outcomes 
as life-years (LY) saved or quality-adjusted life-
years (QALY) saved were analyzed.
In 2011, Signorovitch, et al., performed an indirect 
adjusted comparison of MMR rates from the 
results of the random trials of nilotinib versus 
imatinib (ENESTnd) and dasatinib versus imatinib 
(DASISION), progression-free survival and overall 
survival after 12 months of treatment with nilotinib 
and dasatinib for new diagnoses of CML-CP, during 
which the individual data of the patients treated 
with nilotinib and dasatinib were estimated in order 
for their basic characteristics to coincide, including 
age, gender, ECOG performance status, and 
hematological laboratory values. After comparing the 
efficacy results of patients treated with nilotinib, 300 
mg, twice daily versus those treated with dasatinib, 
100 mg, once daily, they were compared with patients 
treated with imatinib in each trial. This was used to 
evaluate the accuracy of the correlation (negative 
control). Nilotinib was associated with significantly 
higher rates of MMR (56.8% as compared to 45.9%, 
p=0.001) and overall survival (OS) versus dasatinib 
(99.5% vs. 97.3%, p=0.046) (35).
The National Institute for Health and Clinical 
Excellence (NICE) performed a review, taking the 
aforementioned evidence for 12 and 18 months 
and the indirect comparison studies between 
dasatinib and nilotinib. They claimed that there is a 
lack of information to evaluate the long-term results 
in patients (for example, progression-free survival 
Figure 3. Scatter plot for 1,000 iterations 
showing ICER of progression-free life-
years gained (PF-LYs) comparing the use 
of nilotinib vs. imatinib and dasatinib vs. 
imatinib
Figure 4. Scatter plot for 1,000 iterations 
showing ICER of progression-free life-years 
gained (PF-LY) comparing the use of 
nilotinib vs. dasatinib
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PFS, overall survival OS, health-related quality 
of life HRQoL, etc.) and mentioned that the drugs 
were well tolerated, with discontinuation rates 
due to adverse events at <10%. Nevertheless, 
comparing these new technologies with imatinib 
at a dose of 400 mg, and taking the second-line 
usage information from nilotinib, they concluded 
that the use of first-line nilotinib would be cost-
effective in comparison with imatinib. The efficacy 
ratio for dasatinib beyond the €30,000 threshold 
per quality-adjusted life-years (QALY) saved 
(ICER for dasatinib versus imatinib was greater 
than €200,000 per QALY saved) is, therefore, 
not recommended for funding because it is not 
considered to be profitable (36). Finally, NICE 
Committee recommends the use of first-line 
nilotinib for patients with CML, and its use is 
considered profitable for the resources available 
to the NHS (36).
Studies such as those carried out in México 
(Hernández-Rivera G, Aguayo Á, Cantu-Rodríguez 
O, Cervera E, Gomez-Almaguer D, Gutiérrez H, et 
al. PSY24 Cost of care for chronic myeloid leukemia 
(CML) in patients experiencing resistance and/
or intolerance to imatinib from the public health 
system perspective in Mexico. Value Health. 
2010;13:A464), Brasil (Ouissak C, Litalien G, Alves 
MR. PCN35 Cost-effectiveness analysis of dasatinib 
for the treatment of imatinib resistant or intolerant 
CML patients in Brazil. Value Health. 2008;11:A64. 
http://dx.doi.org/10.1016/S1098-3015(10)70213-8), 
Colombia and Venezuela (37), and Chile (38), only 
show second-line results by measuring quality-
adjusted life-years (QALY) gained as an outcome 
when comparing the costs and cost-effectiveness of 
the use of 100 mg/day and 140 mg/day of dasatinib 
with the use of 800 mg/day of nilotinib and a dose 
of imatinib at 800 mg/day in patients who have 
developed resistance and intolerance to normal 
doses of imatinib; they are, therefore, not comparable 
with the results of this study.
With the improvement in the technology, there is 
evidence that treatment results are better in terms of 
molecular response than of cytogenetic response, 
as demonstrated in the ENESTnd study, which has 
established nilotinib as a highly effective agent in 
the first-line treatment of CML (31).
A complete economic analysis was performed that 
presented all of the factors related to the treatment 
and compared the three most common treatment 
options. A double analysis of imatinib was performed 
when comparing it independently with nilotinib and 
dasatinib, with similar results. This allowed for the 
indirect establishment of the relationship between 
the two comparable drugs without losing sight of the 
bias caused by the lack of head-to-head trials data. 
Probability ranges were obtained from clinical 
studies (12-15) and analyzed based on the 
information backed by qualified clinical studies with 
an evidence level of 1++ and an A recommendation 
level according to the SIGN-50 qualification (39). 
Nevertheless, one important limitation is that the 
data corresponds to phase III studies with results 
published after 24 months (13,15), and they are 
used for the long-term analysis. In this sense, the 
interpretation would be similar to that reported in 
the IRIS study for imatinib after the 7-year follow-
up (24); upon viewing the IRIS results and their 
performance, it can be assumed that similar 
performance will continue. 
It is important to recognize that the cost of the 
medications is included in the principal result 
factor, and as of the date of this study, dasatinib 
and imatinib are regulated in Colombia (25) in such 
a manner that the price of nilotinib corresponds to 
an estimated price based on the distributor sales 
prices in that country. 
It would be worthwhile to perform an additional 
quality of life (QoL) analysis of the patients treated 
with nilotinib, which would allow us to establish 
whether, from a cost-utility standpoint, the same 
results are maintained. However, there are no 
published studies to date on the quality of life in 
Colombia for CML, and trying to utilize information 
about preferences in other countries would include 
a significant bias that would make the obtained 
results disputable. Therefore, this is another matter 
that must be researched. Under ideal conditions, 
QoL evaluations should be carried out for patients 
treated with imatinib, nilotinib and dasatinib, and 
they should be compared with each other. 
Keeping the proposed threshold in mind to evaluate 
cost-effectiveness, the ICER obtained from the 
comparison of nilotinib versus imatinib presented it 
as cost-effective in the baseline case conditions. The 
comparison of dasatinib versus imatinib showed an 
ICER with cost-effectiveness that was greater than 
the will to pay. The comparison of nilotinib versus 
dasatinib showed dominance in the majority of cases 
by costing less and offering better results measured 
in progression-free life-years (PF-LY). In this manner, 
from the standpoint of the analyzed outcome, the 
advantage that the use of nilotinib implies over the 
two comparable drugs can be established. 
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In conclusion, nilotinib under baseline case 
conditions was the most effective option out of 
the three analyzed. From a cost standpoint, its 
performance would be one of savings as compared 
to dasatinib and, although it costs more than 
imatinib, its cost-effectiveness shows that the cost 
per progression-free life-year gained would be 
less than the estimated cost of caring for a patient 
in progression. Consequently, for the purposes 
of this analysis, the use of nilotinib at a dose of 
300 mg/BID would be the most recommendable 
option for use in Colombia as first-line treatment 
for CML. 
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